Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Viking Therapeutic (VKTX) PT Raised to $80 at Stifel, '“Best-in-Class” Profile of Injectable VK2735 Stands Firm'
February 27, 2024 12:06 PM ESTStifel analyst Samimy Annabel raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $80.00 (from $35.00) while maintaining a Buy rating.
The analyst comments "Ahead of schedule, VKTX released the Ph.2 VENTURE data for injectable-VK2735, which again demonstrated a highly competitive profile relative to... More
Viking Therapeutics (VKTX) stock surges after phase 2 Venture trial meets primary and secondary endpoints
February 27, 2024 8:40 AM ESTViking Therapeutics (NASDAQ: VKTX) shares surged more than 80% premarket Monday after the company announced positive top-line results from its Phase 2 clinical trial of VK2735.
VK2735 is a medicine that may help treat obesity and other metabolic disorders. It works by targeting to... More
